“The diversity in our clinical trials must mirror the patient communities the treatment hopes to serve,”
Health equity innovation must go beyond the science - https://t.co/V6xFsP1wrM
Heard at @LS_Cares Impact Breakfast: “If we can invest 13 years in developing a drug, we must invest 13 years in developing girls with an interest in STEM”. +100%
“In the last two-to-three years, the whole biotech environment has changed dramatically. In America, until last year, there were a lot of companies going public, and they didn’t need to do deals, so it was all on their own terms" https://t.co/cF908Z56bY
While the pace of new #SPAC offerings seem to have slowed in the second quarter of 2021, they are still positioned as an attractive option for private #biotech & #pharma companies in need of rapid access to capital https://t.co/zrLI3qUTXz
In 2020 biotech IPOs continued to break and establish new records, as more startups went public and raised more cash than ever before. In 2H of 2021, we saw the performance of biotech IPOs plummet. https://t.co/w6He2TOzSb via @BioPharmaDive
So excited that I finally get to unveil my first solo website project. Thank you to the @TrophicComms team for trusting me to see it through and thank you to Ante and his team at @imagemakersmuc for helping me bring the vision to life.
Our newly updated website is finally here! A big thank you to our long-term collaborator, @imagemakersmuc, for bringing our vision to life. Check out https://t.co/NioCgfMpEh to learn more about our capabilities as a strategic corporate #communications partner in the #lifesciences
Congratulations to #Modra Pharmaceuticals on the announcement of Positive Phase 2b data evaluating it's lead candidate #ModraDoc006, an oral #taxane approach for patients living with #mCRPC https://t.co/DsI2ZsiAja
Check out this great article from https://t.co/b5piPJ7knT on how companies such as @OsivaxVaccines are leading the charge in generating #universalvaccines that can protect the population from all current and future strands of #Covid19. https://t.co/kMGBcO9Fmy
#Drugregulations present major challlenges for EU companies hoping for success in the US market. companies require a keen #commercialisation strategy, customizable to the needs of your specific drug. Check out this insightful piece in @pharmaphorum https://t.co/ETuJ7bx4A3
So happy to be apart of this amazing team of communicators and celebrate Trophic's 4th #anniversary. I look forward to what the next year has in store!
Check out this article on how the use of #socialmedia is defined by the value, relevance, & credibility of the content it conveys. https://t.co/Kkzwo4i7Ep
A great article by @VirginiaGewin about the online initiative recognizing the contributions of black scientists and their increasing roles within the various areas of clinical research. Very proud to be #BlackinBiotech#diversity#inclusion
Five researchers who organized and took part in the #BlackinSTEM weeks discuss their movements' impacts and rewards, including career opportunities, collaborations and meaningful institutional actions. https://t.co/HcSsKt8ayx
“When you’re the VC, you’re kind of the kingmaker ... I felt like the entrepreneur needed someone to reach their hand out and say, ‘I’m going to help you with this.’” -- @cngarabedian. This week, @BosBizRowan reports on biotech's new funding models: https://t.co/P5KevGbO9r
A strong team and a compelling #comunications strategy are vital for any #biotech looking to secure institutional #investors to raise their US value. https://t.co/q25VKlvGtR
Great Article on how scientists and farmers are using social media to combat #misinformation posts. Platforms such as LinkedIn and Twitter can be valuable tools for #biotech professionals. https://t.co/VLAgBbm8ZK
Great article from @FierceBiotech examining the efforts made by #biotech and #phama companies to make #DiversityandInclusion a priority and how information can be used in targeted programming and #SocialMedia outreach to achieve higher results. https://t.co/5ZP7rfZUJC
In the wake of the Covid-19 pandemic, companies like @immatics were able to launch successful #IPOlistings, proving there is keen interest from investors in the #biotech space. Checkout the https://t.co/b5piPJ7knT article on whether this "trend" is potentially just the beginning
With record amounts of cash flowing into the #biotech industry, it’s natural to wonder when the funding window will close. According to Simon Goldman, @UCLTF's Investment Director, there’s little reason to assume this window will close at all. Here's why 👇🏻https://t.co/61YjBf6FuI
We provide a range of #IR services, from run-up to #IPO & #investor targeting based on peer analysis, to presentation training & developing financial communications. Visit https://t.co/qnN6qo5SMa for more on our IR/PR capabilities. #LifeSciences
Today the #FDA determines the approval of #Aducanumab. @nytimes published a piece addressing the drug's pros and cons and two other treatment options that are showing promising data in case it is not approved. https://t.co/6wU4VzKoil